DOTmed August 6, 2024
For all its cancer treatment advantages, the business end of proton therapy is synonymous with massive gantries and investment costs in the hundreds of millions. However, new developments from manufacturers are changing the calculus around protons, and ushering in a future where systems may require no gantry at all, and significantly lower upfront costs to providers.
P-Cure and Mevion are among the companies working to reimagine the way protons are delivered. The MEVION S250-FIT cyclotron, developed in partnership with Leo Cancer Care, is self-shielded, and the P-Cure system requires 50% less shielding than a traditional gantry room. B dot Medical in Japan also has a smaller-footprint proton therapy system called the Phemto that utilizes a much smaller gantry than traditional...
Today's Sponsors
Today's Sponsor